Transportable Ex Vivo Normothermic Preservation





The metra® device:
- Recreates a physiological environment
- Enables up to 24 hour preservation
- Enables transplantation of steatotic organs*
- Can improve operating room logistics*
- Can reduce peak AST in the first week post-transplant compared to cold storage*
Following the UK feasibility study, the OrganOx metra device has now been CE marked, used in a large scale European randomised controlled clinical trial, two feasibility trials in Canada and a large scale US clinical trial has recently started. *Ravikumar et al; Am J Transpl. 2016;16:1779-1787
Latest news from OrganOx
Featured
The results of the UK dual centre (Queen Elizabeth Hospital, Birmingham and King's College Hospital, London) feasibility study of the OrganOx metra device have been published in the June 2016 edition of the American Journal of Transplantation. This is the first in man application of this technology, and has been featured on the front cover of the journal.
Access to the article is here: